Dual actions of fibroblast growth factor 19 on lipid metabolism

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 325-332

  Wu, Xinle ^a   Ge, Hongfei ^a   Baribault, Hélène ^a   Gupte, Jamila ^a   Weiszmann, Jennifer ^a   Lemon, Bryan ^a   Gardner, Jonitha ^a   Fordstrom, Preston ^a   Tang, Jie ^a   Zhou, Mingyue ^a   Wang, Minghan ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Adipocyte; Bile acid; Cholesterol; Diabetes; Fat; Glucose regulation; Metabolic disease; Mitogenesis; Obesity; Triglyceride

Indexed keywords

CHOLESTEROL; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 4; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE METABOLISM; LIPID METABOLISM; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CELL LINE; CHOLESTEROL; DIET; FIBROBLAST GROWTH FACTORS; LIPID METABOLISM; LIVER; MALE; MICE; OBESITY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TRIGLYCERIDES;

EID: 84872462425     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M027094     Document Type: Article

References (30)

1. Wu, X., and Y. Li. 2009. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY). 1: 1023-1027.
2. Wu, X., and Y. Li. 2011. Therapeutic utilities of fibroblast growth factor 19. Expert Opin. Ther. Targets. 15: 1307-1316.
3. Asada, M., M. Shinomiya, M. Suzuki, E. Honda, R. Sugimoto, M. Ikekita, and T. Imamura. 2009. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim. Biophys. Acta. 1790: 40-48.
4. Kurosu, H., M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, and M. Kuro-o. 2007. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282: 26687-26695. (Pubitemid 47501965)
5. Lin, B. C., M. Wang, C. Blackmore, and L. R. Desnoyers. 2007. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282: 27277-27284. (Pubitemid 47501977)
6. Wu, X., H. Ge, J. Gupte, J. Weiszmann, G. Shimamoto, J. Stevens, N. Hawkins, B. Lemon, W. Shen, J. Xu, et al. 2007. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282: 29069-29072. (Pubitemid 350043330)
7. Dutchak, P. A., T. Katafuchi, A. L. Bookout, J. H. Choi, R. T. Yu, D. J. Mangelsdorf, and S. A. Kliewer. 2012. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell. 148: 556-567.
8. Fu, L., L. M. John, S. H. Adams, X. X. Yu, E. Tomlinson, M. Renz, P. M. Williams, R. Soriano, R. Corpuz, B. Moffat, et al. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 145: 2594-2603. (Pubitemid 38686202)
9. Kharitonenkov, A., T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, et al. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115: 1627-1635. (Pubitemid 40814671)
10. Ito, S., S. Kinoshita, N. Shiraishi, S. Nakagawa, S. Sekine, T. Fujimori, and Y. I. Nabeshima. 2000. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98: 115-119.
11. Ogawa, Y., H. Kurosu, M. Yamamoto, A. Nandi, K. P. Rosenblatt, R. Goetz, A. V. Eliseenkova, M. Mohammadi, and M. Kuro-o. 2007. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA. 104: 7432-7437. (Pubitemid 47185923)
12. Suzuki, M., Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M. Asada, A. Komi-Kuramochi, S. Oka, and T. Imamura. 2008. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22: 1006-1014. (Pubitemid 351482834)
13. Wu, X., H. Ge, B. Lemon, S. Vonderfecht, H. Baribault, J. Weiszmann, J. Gupte, J. Gardner, R. Lindberg, Z. Wang, et al. 2010. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl. Acad. Sci. USA. 107: 14158-14163.
14. Ge, H., H. Baribault, S. Vonderfecht, B. Lemon, J. Weiszmann, J. Gardner, K. J. Lee, J. Gupte, P. Mookherjee, M. Wang, et al. 2012. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS ONE. 7: e33603.
15. Wu, X., H. Ge, B. Lemon, J. Weiszmann, J. Gupte, N. Hawkins, X. Li, J. Tang, R. Lindberg, and Y. Li. 2009. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc. Natl. Acad. Sci. USA. 106: 14379-14384.
16. Holt, J. A., G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. Donahee, D. Y. Wang, T. A. Mansfield, S. A. Kliewer, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17: 1581-1591. (Pubitemid 36828786)
17. Wu, A. L., S. Coulter, C. Liddle, A. Wong, J. Eastham-Anderson, D. M. French, A. S. Peterson, and J. Sonoda. 2011. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE. 6: e17868.
18. Angelin, B., K. Einarsson, K. Hellstrom, and B. Leijd. 1978. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J. Lipid Res. 19: 1017-1024. (Pubitemid 9059813)
19. Beil, U., J. R. Crouse, K. Einarsson, and S. M. Grundy. 1982. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism. 31: 438-444. (Pubitemid 12155449)
20. Crouse 3rd, J. R. 1987. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am. J. Med. 83: 243-248.
21. Pullinger, C. R., C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. Verhagen, C. R. Rivera, S. J. Mulvihill, M. J. Malloy, et al. 2002. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110: 109-117. (Pubitemid 34743471)
22. Tomlinson, E., L. Fu, L. John, B. Hultgren, X. Huang, M. Renz, J. P. Stephan, S. P. Tsai, L. Powell-Braxton, D. French, et al. 2002. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 143: 1741-1747. (Pubitemid 34415889)
23. Watanabe, M., S. M. Houten, L. Wang, A. Moschetta, D. J. Mangelsdorf, R. A. Heyman, D. D. Moore, and J. Auwerx. 2004. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113: 1408-1418. (Pubitemid 39071696)
24. Lin, Y., R. Havinga, H. J. Verkade, H. Moshage, M. J. Slooff, R. J. Vonk, and F. Kuipers. 1996. Bile acids suppress the secretion of very-low-density lipoprotein by human hepatocytes in primary culture. Hepatology. 23: 218-228. (Pubitemid 26045937)
25. Inagaki, T., M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. Jones, B. Goodwin, J. A. Richardson, et al. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2: 217-225.
26. Kharitonenkov, A. 2009. FGFs and metabolism. Curr. Opin. Pharmacol. 9:805-810.
27. Xu, J., D. J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R. Hecht, Y. S. Li, R. A. Lindberg, et al. 2009. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 58: 250-259.
28. Wu, A. L., G. Kolumam, S. Stawicki, Y. Chen, J. Li, J. Zavala-Solorio, K. Phamluong, B. Feng, L. Li, S. Marsters, L. Kates, N. van Bruggen, M. Leabman, A. Wong, D. West, H. Stern, E. Luis, H. S. Kim, D. Yansura, A. S. Peterson, E. Filvaroff, Y. Wu, and J. Sonoda. 2011. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3: 113ra126.
29. Thi, H. D., T. V. Tselykh, J. Makela, T. H. Huu, V. M. Olkkonen, B. C. Bornhauser, L. Korhonen, N. Zelcer, and D. Lindholm. 2012. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting Saposin-like protein (Msap). J. Biol. Chem. 287: 12602-12611.
30. Veniant, M. M., C. Hale, J. Helmering, M. M. Chen, S. Stanislaus, J. Busby, S. Vonderfecht, J. Xu, and D. J. Lloyd. 2012. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS ONE. 7: e40164.